Alembic Pharmaceuticals is currently trading at Rs. 517.25, up by 11.90 points or 2.35% from its previous closing of Rs. 505.35 on the BSE.
The scrip opened at Rs. 506.60 and has touched a high and low of Rs. 518.00 and Rs. 506.60 respectively. So far 2355 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 664.00 on 27-Sep-2018 and a 52 week low of Rs. 435.10 on 21-Jun-2019.
Last one week high and low of the scrip stood at Rs. 518.00 and Rs. 435.10 respectively. The current market cap of the company is Rs. 9717.05 crore.
The promoters holding in the company stood at 72.97%, while Institutions and Non-Institutions held 14.98% and 12.05% respectively.
Alembic Pharmaceuticals has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Oseltamivir Phosphate Capsules USP, 30 mg (base), 45 mg (base) and 75 mg (base).
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Tamiflu Capsules, 30 mg (base), 45 mg (base) and 75 mg (base), of Hoffman-La Roche, Inc. Oseltamivir Phosphate Capsules USP are indicated for the treatment of acute, uncomplicated illness due to influenza A and B infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. It is also indicated for the prophylaxis of influenza A and B in patients 1 year and older.
According to IQVIA, Oseltamivir Phosphate Capsules has an estimated market size of $ 647 million for twelve months ending December 2018. Alembic now has a total of 97 ANDA approvals (85 final approvals and 12 tentative approvals) from USFDA.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.